Elana Schwartz1, Melanie Charlotte2, Eric Slade3, Deborah Medoff3, Lan Li2, Lisa Dixon4, Amy Kilbourne5, Julie Kreyenbuhl6. 1. VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore MD, 21201, USA. 2. University of Maryland School of Medicine, Department of Psychiatry, Division of Psychiatric Services Research, Baltimore MD, 21201, USA. 3. VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore MD, 21201, USA; University of Maryland School of Medicine, Department of Psychiatry, Division of Psychiatric Services Research, Baltimore MD, 21201, USA. 4. Center for Practice Innovations, New York State Psychiatric Institute, Department of Psychiatry, Columbia University, New York, NY, 10032, USA. 5. Quality Enhancement Research Initiative, VA Health Services Research and Development (HSR&D) Program and Department of Psychiatry, University of Michigan, Ann Arbor, MI, 48109, USA. 6. VA Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore MD, 21201, USA; University of Maryland School of Medicine, Department of Psychiatry, Division of Psychiatric Services Research, Baltimore MD, 21201, USA. Electronic address: jkreyenb@psych.umaryland.edu.
Abstract
OBJECTIVE: To examine gender differences in prescribing of antipsychotic medications (APMs) according to their liability for weight gain and other metabolic side effects. METHOD: We identified 4510 patients with schizophrenia or bipolar disorders receiving usual care in a Veterans Affairs (VA) health care network in the U.S. mid-Atlantic region who initiated treatment with an APM between October 2006 and September 2011. We used multivariable logistic regression to examine gender differences in the likelihood of incident prescription of APMs with low versus medium/high metabolic risk, adjusting for fiscal year of prescribing and selected Veteran demographic, mental health and physical health characteristics. RESULTS: Overall, 58% of women were prescribed an APM with a low risk of metabolic side effects compared to 45% of men (P<.001). In multivariable analysis, women Veterans were 1.47 times as likely as men to be prescribed a low-metabolic-risk APM (95% confidence interval: 1.26-1.73, P<.001). Several demographic and clinical covariates were also independently related to prescribing of APMs by level of metabolic risk. CONCLUSIONS: The results may suggest that prescribing choices for APMs by VA mental health prescribers and female Veterans reflect a growing awareness of the potential adverse health consequences of these treatments in women. Published by Elsevier Inc.
OBJECTIVE: To examine gender differences in prescribing of antipsychotic medications (APMs) according to their liability for weight gain and other metabolic side effects. METHOD: We identified 4510 patients with schizophrenia or bipolar disorders receiving usual care in a Veterans Affairs (VA) health care network in the U.S. mid-Atlantic region who initiated treatment with an APM between October 2006 and September 2011. We used multivariable logistic regression to examine gender differences in the likelihood of incident prescription of APMs with low versus medium/high metabolic risk, adjusting for fiscal year of prescribing and selected Veteran demographic, mental health and physical health characteristics. RESULTS: Overall, 58% of women were prescribed an APM with a low risk of metabolic side effects compared to 45% of men (P<.001). In multivariable analysis, women Veterans were 1.47 times as likely as men to be prescribed a low-metabolic-risk APM (95% confidence interval: 1.26-1.73, P<.001). Several demographic and clinical covariates were also independently related to prescribing of APMs by level of metabolic risk. CONCLUSIONS: The results may suggest that prescribing choices for APMs by VA mental health prescribers and female Veterans reflect a growing awareness of the potential adverse health consequences of these treatments in women. Published by Elsevier Inc.
Entities:
Keywords:
Antipsychotic medication; Serious mental illness; Veterans; Women’s health
Authors: Nancy H Covell; Ellen M Weissman; Bonnie Schell; Brian H McCorkle; W Thomas Summerfelt; Peter J Weiden; Susan M Essock Journal: Adm Policy Ment Health Date: 2007-09
Authors: T Scott Stroup; Joseph P McEvoy; Kimberly D Ring; Robert H Hamer; Lisa M LaVange; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Abraham M Nussbaum; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2011-07-18 Impact factor: 18.112
Authors: Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller Journal: Schizophr Bull Date: 2009-12-02 Impact factor: 9.306
Authors: Gail L Daumit; Jeanne M Clark; Donald M Steinwachs; Camelia M Graham; Anthony Lehman; Daniel E Ford Journal: J Nerv Ment Dis Date: 2003-12 Impact factor: 2.254
Authors: John W Newcomer; Joao Alberto Campos; Ronald N Marcus; Christopher Breder; Robert M Berman; Wendy Kerselaers; Gilbert J L'italien; Marleen Nys; William H Carson; Robert D McQuade Journal: J Clin Psychiatry Date: 2008-07 Impact factor: 4.384
Authors: Elisheva R Danan; Erin E Krebs; Kristine Ensrud; Eva Koeller; Roderick MacDonald; Tina Velasquez; Nancy Greer; Timothy J Wilt Journal: J Gen Intern Med Date: 2017-09-14 Impact factor: 5.128